In terms of medical applications, genome editing using ZFNs entered phase I clinical trials to knockout the C-C chemokine receptor type 5 (CCR5) gene, a co-receptor expressed on CD4+ T lymphocytes, aiding the entry of human immunodeficiency virus to develop acquired immunodeficiency syndrome (AIDS). This evidence concerns the gene CCR5 and AIDS.